However, brusatol-exposed CD34+ AML cells showed comparable reduced GSH levels and redox (GSH/GSSG) ratio when compared with normal PBMCs, suggesting that the increased reducing power is diminished upon brusatol exposure (Figure 4H). This evidence concerns the gene CD34 and acute myeloid leukemia.